Evidence map›Paper›PMID 39618424›Full record

ArticleMolecular therapy. Methods & clinical development2024

Modulation of AAV transduction and integration targeting by topoisomerase poisons.

Aradhana Kasimsetty, Young Hwang, John K Everett, Alexander G McFarland, Sonja A Zolnoski, Tianyu Lu, Aoife M Roche, Pedro Manuel Martínez-García, Denise E Sabatino, Frederic D Bushman

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aradhana KasimsettyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Young HwangDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
John K EverettDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Alexander G McFarlandDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sonja A ZolnoskiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tianyu LuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Aoife M RocheDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Pedro Manuel Martínez-GarcíaCentro Andaluz de Biología del Desarrollo, Consejo Superior de Investigaciones Científicas and Universidad Pablo de Olavide, Sevilla, Spain.
Denise E SabatinoThe Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Funding

Preserving Genome Integrity In AAV-Mediated Gene TherapyR01HL160748 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI BUSHMAN, FREDERIC D, SABATINO, DENISE E · 2022 to 2025
$2.6M
NHLBI NIH HHS R01 HL160748
6 · The paper itself

Abstract

Adeno-associated virus (AAV) is a widely used vehicle for gene delivery, lending interest to developing methods for enhancing AAV transduction and transgene expression. Here, we profile the function of several topoisomerase poisons, which are small molecules that stabilize topoisomerase enzymatic intermediates, where topoisomerase enzymes are covalently bound at chromosomal DNA breaks. As previously observed, we found that the topoisomerase poisons camptothecin (CPT), doxorubicin (DOX), and etoposide (ETO) increased AAV transduction in cultured cell models. DOX and ETO, small molecules that specifically inhibit type II topoisomerases and so stabilize double-strand breaks, were found to boost integration of AAV DNA into the host cell chromosome. Analysis of integration site distributions showed that integration targeting was altered, so that integration in the presence of DOX or ETO was favored near actively transcribed regions. Locations of topoisomerase II binding sites were inferred from genomic data using a novel machine learning platform, and integration in the presence of DOX or ETO was found to be selectively favored near inferred topoisomerase II binding sites. These data help guide development of improved transduction protocols using these reagents and establish that DOX and ETO can control AAV integration targeting.

Indexed as

AAV gene therapyAAV integrationAAV vectorsadriamycincamptothecindoxorubicinetoposidemachine learningshort-read sequencingtopoisomerase

Identifiers

PMID39618424
PMCPMC11607603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.